Safety · Red flags
Eight concrete warning signs that an online GLP-1 telehealth provider may not be safe or transparent — each checkable before you pay.
Updated June 1, 2026 · Reviewed by the GLP1 One Telehealth Editorial Team
What are the biggest GLP-1 telehealth red flags?
The biggest red flags are: no licensed provider review, no pharmacy disclosure, claims that compounded medication is “FDA-approved,” marketing it as “generic Ozempic” or “generic Zepbound,” unrealistic weight-loss promises, hidden membership fees, pricing hidden behind an intake form, and no refund or cancellation policy.
Educational use only. This page is for educational purposes only and does not provide medical advice. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products and should only be prescribed when clinically appropriate by a licensed healthcare provider.
Each maps to a real risk — unsupervised prescribing, unverifiable sourcing, deceptive marketing, or hidden cost. The “generic Ozempic” framing is especially misleading; there is no generic Ozempic.
Run the provider checklist and compare pricing with the GLP-1 teaser pricing explained reference.
No. There is no generic Ozempic, and compounded semaglutide is not an FDA-approved finished product.
Intake-gated pricing can hide a high maintenance cost; transparent providers publish their pricing.
Some providers add membership or dose-based fees; confirm the all-in monthly price before enrolling.